Higher radiotherapy dose to the base of the heart was significantly associated with worse overall survival (95% CI 1.02-1.21), an effect exacerbated by lower baseline ejection fraction (p=0.04).
RCT (n=205)
Yes
Does baseline left ventricular ejection fraction modify the impact of heart base radiation dose on overall survival in patients with inoperable stage II or III NSCLC?
Preexisting cardiac dysfunction (lower baseline LVEF) exacerbates the negative impact of radiation dose to the base of the heart on overall survival in patients with NSCLC.
p-value: p=0.04
INTRODUCTION: Heart dose has emerged as an independent predictor of overall survival in patients with NSCLC treated with radiotherapy. Several studies have identified the base of the heart as a region of enhanced dose sensitivity and a potential target for cardiac sparing. We present a dosimetric analysis of overall survival in the multicenter, randomized PET-Plan trial (NCT00697333) and for the first time include left ventricular ejection fraction (EF) at baseline as a metric of cardiac function. METHODS: A total of 205 patients with inoperable stage II or III NSCLC treated with 60 to 72 Gy in 2 Gy fractions were included in this study. A voxel-wise image-based data mining methodology was used to identify anatomical regions where higher dose was significantly associated with worse overall survival. Univariable and multivariable Cox proportional hazards models tested the association of survival with dose to the identified region, established prognostic factors, and baseline cardiac function. RESULTS: , 95% confidence interval: 1.02-1.21) were significantly associated with overall survival. There was a significant interaction between EF and region dose (p = 0.04) for survival, with contrast plots revealing a larger effect of region dose on survival in patients with lower EF values. CONCLUSIONS: This work validates previous image-based data mining studies by revealing a strong association between dose to the base of the heart and overall survival. For the first time, an interaction between baseline cardiac health and heart base dose was identified, potentially suggesting preexisting cardiac dysfunction exacerbates the impact of heart dose on survival.
Craddock et al. (Sun,) conducted a rct in inoperable stage II or III NSCLC (n=205). Radiotherapy was evaluated on overall survival (95% CI 1.02-1.21, p=0.04). Higher radiotherapy dose to the base of the heart was significantly associated with worse overall survival (95% CI 1.02-1.21), an effect exacerbated by lower baseline ejection fraction (p=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: